Welcome to our dedicated page for DFP Holdings SEC filings (Ticker: DFPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DFP Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DFP Holdings's regulatory disclosures and financial reporting.
The Oncology Institute, Inc. reported that its Board of Directors, by unanimous written consent, appointed Mark D. Stolper to fill a vacancy on the Board effective January 2, 2026. The Board’s Nominating and Corporate Governance Committee determined that he meets Nasdaq’s independence requirements and has the expertise to contribute effectively. He has been appointed to the Audit Committee, will serve as its Chairman, and has been designated the Audit Committee financial expert.
Mr. Stolper’s term runs until the next annual meeting of stockholders, when he is expected to be nominated as part of management’s slate. He will participate in the company’s non-employee director compensation program, receiving $75,000 per year, paid quarterly, plus restricted stock unit awards for his Board service and role as Audit Committee Chairman, to be granted at a later date. The company also issued a press release on January 5, 2026 announcing his appointment.
The Oncology Institute, Inc. reported that its Board of Directors, by unanimous written consent, appointed Mark D. Stolper to fill a vacancy on the Board effective January 2, 2026. The Board’s Nominating and Corporate Governance Committee determined that he meets Nasdaq’s independence requirements and has the expertise to contribute effectively. He has been appointed to the Audit Committee, will serve as its Chairman, and has been designated the Audit Committee financial expert.
Mr. Stolper’s term runs until the next annual meeting of stockholders, when he is expected to be nominated as part of management’s slate. He will participate in the company’s non-employee director compensation program, receiving $75,000 per year, paid quarterly, plus restricted stock unit awards for his Board service and role as Audit Committee Chairman, to be granted at a later date. The company also issued a press release on January 5, 2026 announcing his appointment.
Oncology Institute, Inc. reported an updated insider transaction for its Chief Financial Officer, who serves as an officer of the company. On 01/02/2026, the CFO disposed of 244 shares of common stock at a price of $3.67 per share in a transaction coded "J." After this sale, the CFO beneficially owned 235,125 shares of common stock directly.
The company explains that the issuer executed this sale to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award on January 1, 2026. The filing is marked as an amendment to correct the transaction code, the number of shares sold, and the sale price from an earlier report filed on January 5, 2026.
The Oncology Institute, Inc. chief financial officer reports a small stock sale linked to taxes. On January 2, 2026, the reporting officer sold 247 shares of Oncology Institute common stock at a price of $3.56 per share. After this transaction, the officer beneficially owned 235,122 shares directly.
The filing notes that the proceeds from this sale were used to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award on January 1, 2026. This indicates the transaction was tied to compensation-related tax obligations rather than a discretionary reduction in holdings.
The Oncology Institute, Inc. chief financial officer reports a small stock sale linked to taxes. On January 2, 2026, the reporting officer sold 247 shares of Oncology Institute common stock at a price of $3.56 per share. After this transaction, the officer beneficially owned 235,122 shares directly.
The filing notes that the proceeds from this sale were used to cover tax liabilities arising from the vesting of a restricted stock unit (RSU) award on January 1, 2026. This indicates the transaction was tied to compensation-related tax obligations rather than a discretionary reduction in holdings.
Oncology Institute, Inc. director Brad Hively reported selling 13,333 shares of common stock on December 15, 2025. The shares were sold at a volume‑weighted average price of $3.771921 per share, with actual sale prices ranging from $3.770 to $3.785. He used the proceeds to pay tax liabilities that arose from the vesting of a restricted stock unit (RSU) award on November 20, 2025, indicating the transaction was primarily tax-related.
After this sale, Hively beneficially owns 683,721 shares of Oncology Institute common stock, held directly.
TOI has a shareholder planning to sell 13,333 shares of common stock under Rule 144.
The shares were acquired as restricted stock from the issuer on 11/21/2025 and are planned to be sold around 12/15/2025 through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $50,290.74. The issuer had 98,381,340 shares of common stock outstanding.
TOI has a shareholder planning to sell 13,333 shares of common stock under Rule 144.
The shares were acquired as restricted stock from the issuer on 11/21/2025 and are planned to be sold around 12/15/2025 through Morgan Stanley Smith Barney LLC on NASDAQ, with an aggregate market value of $50,290.74. The issuer had 98,381,340 shares of common stock outstanding.
Oncology Institute, Inc. director Gabriel Ling filed a Form 4 as a single reporting person in connection with Oncology Institute, Inc. common stock. The filing lists Ling’s role as a director of the company and shows an earliest transaction date of 12/01/2025, but the transaction tables in the excerpt do not display any specific share amounts, prices, or derivative positions.
Oncology Institute, Inc. director Gabriel Ling filed a Form 4 as a single reporting person in connection with Oncology Institute, Inc. common stock. The filing lists Ling’s role as a director of the company and shows an earliest transaction date of 12/01/2025, but the transaction tables in the excerpt do not display any specific share amounts, prices, or derivative positions.
The Oncology Institute, Inc. reported that board member Gabriel Ling resigned from its Board of Directors on November 26, 2025, with the resignation effective December 1, 2025. The company stated that Mr. Ling’s decision was not the result of any disagreement regarding its operations, policies, or practices, indicating a non-controversial departure. On December 1, 2025, the company issued a press release announcing his resignation and furnished it as an exhibit to this report.
The Oncology Institute, Inc. reported that board member Gabriel Ling resigned from its Board of Directors on November 26, 2025, with the resignation effective December 1, 2025. The company stated that Mr. Ling’s decision was not the result of any disagreement regarding its operations, policies, or practices, indicating a non-controversial departure. On December 1, 2025, the company issued a press release announcing his resignation and furnished it as an exhibit to this report.
Oncology Institute, Inc. (TOI) reported equity awards to a director on a Form 4. Director Anne McGeorge acquired 67,901 shares of common stock in the form of restricted stock units that vest in full on the issuer’s 2026 annual stockholder meeting date, subject to continued service. She also received 40,123 restricted stock units that were fully vested upon grant, both at a stated price of $0 per share. Following these transactions, she beneficially owned 291,370 shares of common stock directly.
Oncology Institute, Inc. (TOI) director reports new stock awards. A board member filed a Form 4 disclosing two grants of common stock in the form of restricted stock units on 11/20/2025. One award covers 50,926 restricted stock units that vest in full on the company’s 2026 annual stockholder meeting date, assuming continued service. The second award covers 40,123 restricted stock units that were fully vested upon grant. Both awards are shown at a price of $0 per share, reflecting that they are equity compensation rather than open-market purchases. After these grants, the director beneficially owns 268,302 shares of common stock in direct ownership.
Oncology Institute, Inc. (TOI) director equity grant reported
A director of Oncology Institute, Inc. reported receiving new equity awards in the form of restricted stock units (RSUs). On 11/20/2025, the reporting person acquired 46,296 shares of common stock through RSUs that will vest in full on the company’s 2026 annual stockholder meeting date, conditioned on continued service. On the same date, the director also acquired 37,037 fully vested RSUs, with no cash price per share reported for either grant. Following these transactions, the director beneficially owns 333,539 shares of TOI common stock directly.